NYSE: HUMHumana

    Humana Q3 2026 Results: Net Income $162 Million on Revenue of $41.16 Billion

    • US stocks
    • Earnings
    • Health Care

    Humana (NYSE: HUM) reported GAAP revenue of $41.2 billion and GAAP net income attributable to Humana of $162.0 million for its third quarter of 2026, the quarter ended 30 Sep 2026, and it said on 6 Nov 2026 in its results release. GAAP diluted earnings per share were $1.33, and the company's adjusted loss per share, a company-defined measure, was $0.70.

    Key highlights

    • Revenue (GAAP): $41.2 billion, up 26.1% YoY and 0.7% QoQ
    • Net income attributable to Humana (GAAP): $162.0 million, down 16.9% YoY and 76.7% QoQ
    • Diluted EPS (GAAP): $1.33, down 17.9% YoY and 76.8% QoQ
    • Adjusted EPS (company-defined): a loss of $0.70 per share

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue41,155.032,649.0+26.1%40,867.0+0.7%
    75.0400.0-81.2%1,360.0-94.5%
    162.0195.0-16.9%694.0-76.7%
    Diluted EPS ($)1.331.62-17.9%5.73-76.8%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    GAAP revenue rose 26.1% from a year earlier, to $41.2 billion from $32.6 billion, and rose 0.7% from the previous quarter, to $41.2 billion from $40.9 billion. GAAP operating income fell 81.2% from a year earlier, to $75.0 million from $400.0 million, and fell 94.5% from the previous quarter's $1.36 billion.

    Operating income was 0.2% of revenue this quarter, against 1.2% a year earlier, 1.0 percentage points lower. Net income was 0.4% of revenue this quarter, against 0.6% a year earlier, 0.2 percentage points lower.

    Adjusted figures exclude put/call valuation adjustments

    The company's adjusted (non-GAAP) pretax result was a loss of $104 million, against GAAP pretax income of $216 million. Its reconciliation subtracts $358 million of non-cash put/call valuation adjustments and adds back $25 million of value creation costs, $10 million of amortization and $3 million of impairment charges.

    Insurance segment posted a loss while CenterWell income fell

    The Insurance segment reported a GAAP loss from operations of $303 million, against income of $251 million a year earlier, on revenue of $39.1 billion, against $31,189 million. Its benefit ratio was 93.7%, against 91.1%, which the company said was favorable to its guidance of 'slightly above 94 percent'.

    The company named three factors for the higher benefit ratio: the Star Ratings revenue headwind for Bonus Year 2026, individual Medicare Advantage membership growth and anticipated lower favorable prior period development.

    CenterWell revenue was $7.16 billion, against $5,879 million, and its GAAP income from operations was $243 million, against $305 million.

    Cash flow rose and full-year EPS guidance was raised

    The company now expects GAAP diluted EPS of at least $15.09 for FY 2026, up from at least $6.52, and adjusted EPS of at least $9.50, up from at least $9.00. It attributes the expected year-over-year decline in adjusted EPS to the Star Ratings headwind for Bonus Year 2026, net of mitigation.

    Operating cash flow for the nine months was $5.38 billion, against $2,573 million, which the company attributed to favorable working capital, mainly an increase in the incurred but not reported (IBNR) balance and collection of receivables, together with a modest rise in GAAP earnings.

    Inference

    Diluted EPS fell 17.9% from a year earlier, a steeper drop than the 16.9% fall in net income. The weighted diluted share count was 121,828 thousand for the quarter, against 120,745 thousand a year earlier. For the nine months, common stock repurchases were $110 million and dividends paid were $320 million.

    The release does not state a dividend declaration or a new buyback authorization. The next dated step it gives is the fourth quarter of 2026, when the company expects to record a noncash initial option liability of $2.14 per share tied to its joint venture with HPS Investment Partners, a subsidiary of BlackRock.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts